Longevity of antibody and cytokine responses following vaccination with high potency emergency FMD vaccines.

The ability of high potency emergency foot-and-mouth disease (FMD) vaccines to promote sustainable immune responses in sheep and pigs following a single application was examined. All vaccine formulations induced a rapid seroconversion in both species, as expected, which was maintained at near peak titres for up to 6 months in sheep and 7 months in pigs. The Montanide ISA 206 formulation gave the best results in sheep. Vaccinated pigs challenged with homologous FMDV were protected from disease at 7 months post vaccination. Systemic levels of cytokines IL-6, IL-8, and in some pigs IL-12, increased following vaccination and were often maintained at an increased level for the duration of the trials. These initial results suggest that high potency vaccines may promote longer lasting immunity than the conventional lower potency vaccines in ruminants and a comparable response in pigs. Results indicate that in an outbreak situation, should emergency vaccination be done with these high potency vaccines, protection should be conferred for a long enough period for the outbreak to be brought under control without the need to revaccinate. Given the increased interval for re-vaccination the use of high potency vaccines for routine prophylactic campaigns could provide a more cost-effective and efficient means of maintaining herd immunity and is an area thus worthy of further examination.

[1]  S. Golding,et al.  Radial immuno-diffusion and serum-neutralisation techniques for the assay of antibodies to swine vesicular disease. , 1976, Research in veterinary science.

[2]  W. Snowdon.  Growth of Foot-and-Mouth Disease Virus in Monolayer Cultures of Calf Thyroid Cells , 1966, Nature.

[3]  W. K. Yong.  Animal Parasite Control Utilizing Biotechnology , 1992 .

[4]  R. Kitching,et al.  Isotype-specific antibody responses to foot-and-mouth disease virus in sera and secretions of ‘carrier’ and ‘non-carrier’ cattle , 1996, Epidemiology and Infection.

[5]  G. Opdenakker,et al.  The chemotactic activity for granulocytes produced by virally infected fibroblasts is identical to monocyte‐derived interleukin 8 , 1989, European journal of immunology.

[6]  S. Alexandersen,et al.  Further studies to quantify the dose of natural aerosols of foot-and-mouth disease virus for pigs , 2002, Epidemiology and Infection.

[7]  P. Barnett,et al.  International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants. , 1996, Vaccine.

[8]  P. Barnett,et al.  Emergency vaccination against foot-and-mouth disease: rate of development of immunity and its implications for the carrier state. , 1994, Vaccine.

[9]  J. Cox,et al.  Adjuvants--a classification and review of their modes of action. , 1997, Vaccine.

[10]  M. Francis,et al.  Antibody response of pigs to foot-and-mouth disease oil emulsion vaccine: the antibody classes involved. , 1982, Research in veterinary science.

[11]  J. Salt,et al.  Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission. , 1998, Vaccine.

[12]  H. Carabin,et al.  A review of emergency foot-and-mouth disease (FMD) vaccines. , 2002, Vaccine.

[13]  R. DiMarchi,et al.  Isotype responses of infected, virus-vaccinated and peptide-vaccinated cattle to foot-and-mouth disease virus. , 1990, Vaccine.

[14]  S. Alexandersen,et al.  Natural aerosol transmission of foot-and-mouth disease virus to pigs: minimal infectious dose for strain O1 Lausanne , 2002, Epidemiology and Infection.

[15]  K. McCullough,et al.  Further studies on the early protective responses of pigs following immunisation with high potency foot and mouth disease vaccine. , 2002, Vaccine.

[16]  J. Snick,et al.  Interleukin-6: an overview. , 1990, Annual review of immunology.

[17]  K. Cowan,et al.  Antibody response to viral antigens. , 1973, Advances in immunology.

[18]  T. Doel,et al.  Optimisation of the immune response to foot-and-mouth disease vaccines. , 1999, Vaccine.

[19]  W. König,et al.  Cytokine (IL-8, IL-6, TNF-alpha) and soluble TNF receptor-I release from human peripheral blood mononuclear cells after respiratory syncytial virus infection. , 1995, Immunology.

[20]  C. Janeway,et al.  Innate Immunity: The Virtues of a Nonclonal System of Recognition , 1997, Cell.

[21]  Doel Tr.  NATURAL AND VACCINE-INDUCED IMMUNITY TO FOOT AND MOUTH DISEASE : THE PROSPECTS FOR IMPROVED VACCINES , 1996 .

[22]  S. Alexandersen,et al.  Relative resistance of pigs to infection by natural aerosols of FMD virus , 2001, Veterinary Record.

[23]  E. C. Anderson,et al.  Immune response of pigs to inactivated foot-and-mouth disease vaccines. Response to emulsion vaccines. , 1971, Research in veterinary science.

[24]  P. McKercher,et al.  Foot-and-mouth disease in swine , 1967, Archiv für die gesamte Virusforschung.

[25]  A. Donaldson,et al.  Air sampling of pigs infected with foot-and-mouth disease virus: comparison of Litton and cyclone samplers. , 1982, Research in Veterinary Science.

[26]  S. Barteling,et al.  Developments in foot-and-mouth disease vaccines. , 1991, Vaccine.

[27]  A. Choi,et al.  Influenza virus A infection induces interleukin‐8 gene expression in human airway epitheial cells , 1992 .

[28]  M. Baggiolini,et al.  Interleukin-8 and the chemokine family. , 1995, International journal of immunopharmacology.